Abaloparatide (Tymlos): Uses, Evidence, and Side Effects

Osteoporosis raises the risk of fractures that can affect mobility and independence, and treatment options that actively build new bone are limited. Abaloparatide is one such option, approved for people at high risk of fracture who need more than standard therapy.

Key takeaways

• Abaloparatide is an FDA-approved PTHrP(1-34) analog marketed under the brand name Tymlos.
• It is approved for postmenopausal women with osteoporosis at high fracture risk and for men with osteoporosis at high fracture risk.
• It works by activating the PTH1 receptor to stimulate bone-forming osteoblast activity.
• Clinical development includes 26 registered trials, among them a completed Phase 3 extension study.
• Reported side effects most often involve headache, nausea, dizziness, and fatigue, based on adverse event reports rather than confirmed causation.

What Abaloparatide Is

Abaloparatide belongs to a drug class known as parathyroid hormone-related peptide analogs. It is designed to mimic part of the natural PTHrP molecule and bind to the PTH1 receptor on bone cells. This activates a signaling pathway inside those cells that promotes new bone formation on both trabecular and cortical bone surfaces. In animal studies, this activity translated into measurable increases in bone mineral density and bone mineral content.

What Abaloparatide Is Approved For

Abaloparatide, sold as Tymlos, is approved to treat postmenopausal women with osteoporosis who are at high risk for fracture, including those who have not responded to or cannot tolerate other osteoporosis therapies. It is also approved to increase bone density in men with osteoporosis who meet the same high-risk or treatment-failure criteria. The label does not carry a boxed warning.

What The Evidence Shows

Abaloparatide has been studied across 26 registered clinical trials. Among these, a completed Phase 3 extension trial followed participants with osteoporosis for 24 months to assess longer-term effects after initial treatment. Other studies in the trial record include early-phase pharmacokinetic work comparing abaloparatide formulations in healthy adults.

Reported Side Effects

Adverse event reports for abaloparatide most commonly describe headache (5,123 reports), nausea (3,913), and dizziness (3,860), alongside fatigue (3,419). Cardiovascular-type reports such as increased heart rate (2,593) and palpitations (2,225) also appear, along with joint pain (arthralgia, 2,343). A notable share of reports involve dose omission issues (2,654) rather than a physical symptom. These figures reflect the number of reports submitted to a surveillance database, not confirmed rates of occurrence or proof that abaloparatide caused the event.